Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content

from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:23:59 ON 06 JAN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:24:19 ON 06 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JAN 2008 HIGHEST RN 960040-46-4
DICTIONARY FILE UPDATES: 4 JAN 2008 HIGHEST RN 960040-46-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10521896.str



chain nodes :
29 30 31 32 33 34 35
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
22 23 24 25 26 27 28
chain bonds :
2-32 7-34 8-12 15-35 19-29 22-34 27-31 29-30 30-31 32-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16
12-13 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22 23-24
23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
2-32 7-34 19-29 22-34 23-24 23-28 24-25 25-26 26-27 27-28 27-31
29-30
exact bonds :
8-12 15-35 30-31 32-33
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16
12-13 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 11 : 17 : 23 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS
34:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

```
=> s l1
SAMPLE SEARCH INITIATED 15:24:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       11 TO ITERATE

100.0% PROCESSED       11 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           22 TO      418
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 15:24:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      256 TO ITERATE

100.0% PROCESSED      256 ITERATIONS                                48 ANSWERS
SEARCH TIME: 00.00.01

L3           48 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'CAPLUS' ENTERED AT 15:25:01 ON 06 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Jan 2008  VOL 148 ISS 2
FILE LAST UPDATED: 4 Jan 2008  (20080104/ED)
```

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 6 L3

=> d l4 ibib abs hitstr hitind 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:652149 CAPLUS
DOCUMENT NUMBER: 147:268307
TITLE: Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
AUTHOR(S): Richardson, Timothy I.; Frank, Scott A.; Wang, Minmin; Clarke, Christian A.; Jones, Scott A.; Ying, Bai-Ping; Kohlman, Dan T.; Wallace, Owen B.; Shepherd, Timothy A.; Dally, Robert D.; Palkowitz, Alan D.; Geiser, Andrew G.; Bryant, Henry U.; Henck, Judith W.; Cohen, Ilene R.; Rudmann, Daniel G.; McCann, Denis J.; Coutant, David E.; Oldham, Samuel W.; Hummel, Conrad W.; Fong, Kin C.; Hinklin, Ronald; Lewis, George; Tian, Hongqi; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(13), 3544-3549
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compds. with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.
IT 648904-56-7P 648904-79-4P 648905-29-7P 770708-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Structure-activity relationships of SERMs optimized for uterine

antagonism and ovarian safety)
RN 648904-56-7 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648904-79-4 CAPLUS
CN 2-Naphthalenol, 6-[4-(ethylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-29-7 CAPLUS
CN 2-Naphthalenol, 6-[4-[(1-methylethyl)sulfonyl]phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 770708-13-9 CAPLUS
CN Benzenesulfonamide,
4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-
naphthalenyl]-N,N-dimethyl- (CA INDEX NAME)



CC 1-3 (Pharmacology)
Section cross-reference(s): 27
IT 606130-99-8P 648904-56-7P 648904-79-4P
648905-29-7P 648906-06-3P 648906-10-9P 688734-86-3P
752181-73-0P 770708-13-9P 861930-36-1P 861930-46-3P
862073-15-2P 862081-59-2P 862129-77-9P 862129-80-4P
862129-85-9P
862129-87-1P 862130-04-9P 862155-76-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(Structure-activity relationships of SERMs optimized for uterine
antagonism and ovarian safety)
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1318447 CAPLUS
DOCUMENT NUMBER: 144:184922
TITLE: Androgen dependent mammary gland virilism in rats
given the selective estrogen receptor modulator

LY2066948 hydrochloride

AUTHOR(S): Rudmann, Daniel G.; Cohen, Ilene R.; Robbins, Michelle R.; Coutant, David E.; Henck, Judith W.

CORPORATE SOURCE: Department of Pathology, Lilly Research Laboratories, Division of Eli Lilly and Co., Greenfield, IN, 46140, USA

SOURCE: Toxicologic Pathology (2005), 33(6), 711-719
CODEN: TOPADD; ISSN: 0192-6233

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A selective estrogen receptor modulator (SERM) is a nonsteroidal compound with tissue specific estrogen receptor (ER) agonist or antagonist activities. In animals, SERMs may produce morphol. changes in hormonally-sensitive tissues like the mammary gland. Mammary glands from female rats given the SERM LY2066948 hydrochloride (LY2066948) for 1 mo at ≥ 175 mg/kg had intralobular ducts and alveoli lined by multiple layers of vacuolated, hypertrophied epithelial cells, resembling in part the morphol. of the normal male rat mammary gland. We hypothesized that these SERM-mediated changes represented an androgen-dependent virilism of the female rat mammary gland. To test this hypothesis, the androgen receptor antagonist flutamide was co-administered with LY2066948 (175 mg/kg) to female rats for 1 mo. Female rats given SERM alone had hyperandrogenemia and the duct and alveolar changes described here. Flutamide cotreatment did not affect serum androgen levels but completely blocked the SERM-mediated mammary gland change. In the mouse, a species that does not have the sex-specific differences in the mammary gland observed in the rat, SERM treatment resulted in hyperandrogenemia but did not alter mammary gland morphol. These studies demonstrate that LY2066948 produces species-specific, androgen-dependent mammary gland virilism in the female rat.

IT 648904-56-7, LY2066948
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective estrogen receptor modulator LY2066948 hydrochloride produced hyperandrogenemia and androgen-dependent virilism of mammary gland in

female Fischer 344 rat)
RN 648904-56-7 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



CC 2-4 (Mammalian Hormones)
IT 648904-56-7, LY2066948
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective estrogen receptor modulator LY2066948 hydrochloride produced
hyperandrogenemia and androgen-dependent virilism of mammary gland in
female Fischer 344 rat)
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1055907 CAPLUS
DOCUMENT NUMBER: 143:415737
TITLE: A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity
in bone, and minimal ovarian stimulation
AUTHOR(S): Geiser, Andrew G.; Hummel, Conrad W.; Draper, Michael
W.; Henck, Judith W.; Cohen, Ilene R.; Rudmann, Daniel

G.; Donnelly, Kevin B.; Adrian, Mary D.; Shepherd, Timothy A.; Wallace, Owen B.; McCann, Denis J.; Oldham, Samuel W.; Bryant, Henry U.; Sato, Masahiko; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, 46285, USA
SOURCE: Endocrinology (2005), 146(10), 4524-4535
CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The use of selective estrogen receptor modulators for the treatment of estrogen-dependent diseases in premenopausal women has been hindered by undesirable ovarian stimulation and associated risks of ovarian cysts. The authors have identified a selective estrogen receptor modulator compound (LY2066948) that is a strong estrogen antagonist in the uterus yet has minimal effects on the ovaries of rats. LY2066948 binds with high affinity to both estrogen receptors and has potent estrogen antagonist activity in human uterine and breast cancer cells. Oral administration of LY2066948 to immature rats blocked uterine weight gain induced by ethynyl estradiol with an ED50 of 0.07 mg/kg. Studies in mature rats demonstrated that LY2066948 decreases uterine weight by 51% after 35 d treatment, confirming potent uterine antagonist activity over several estrus cycles. This strong uterine response contrasted with the minimal effects on the ovaries: serum estradiol levels remained within the normal range, whereas histol. evaluation showed granulosa cell hyperplasia in few of the rats. Bone studies demonstrated that LY2066948 prevented ovariectomy-induced bone loss and treatment of ovary-intact rats caused no bone loss, confirming estrogen receptor agonist skeletal effects. Collectively, these data show that LY2066948 exhibits a tissue-specific profile consistent with strong antagonist activity in the uterus, agonist activity in bone, and minimal effects in the ovaries.
IT 648904-56-7, LY 2066948
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation)
RN 648904-56-7 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



CC 1-6 (Pharmacology)
Section cross-reference(s): 2
IT 648904-56-7, LY 2066948
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation)
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1051070 CAPLUS
DOCUMENT NUMBER: 143:359450
TITLE: A Selective Estrogen Receptor Modulator Designed for
the Treatment of Uterine Leiomyoma with Unique Tissue
Specificity for Uterus and Ovaries in Rats
AUTHOR(S): Hummel, Conrad W.; Geiser, Andrew G.; Bryant, Henry U.; Cohen, Ilene R.; Dally, Robert D.; Fong, Kin Chiu;
Frank, Scott A.; Hinklin, Ronald; Jones, Scott A.; Lewis, George; McCann, Denis J.; Rudmann, Daniel G.;
Shepherd, Timothy A.; Tian, Hongqi; Wallace, Owen B.;

Wang, Minmin; Wang, Yong; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(22), 6772-6775
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:359450
GI



I

AB The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. Compound (I, LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, resp.) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histol. evaluation.

IT 648904-58-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(selective estrogen receptor modulator designed for treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats)

RN 648904-58-9 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



IT 648904-56-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(selective estrogen receptor modulator designed for treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries
in rats)
RN 648904-56-7 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



CC 1-3 (Pharmacology)
Section cross-reference(s): 27, 75
IT 648904-58-9P 861930-45-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(selective estrogen receptor modulator designed for treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries
in rats)
IT 194594-62-2P 648904-46-5P 648904-47-6P 648904-48-7P 648904-49-8P
648904-52-3P 648904-56-7P 648905-79-7P 648905-80-0P
648905-81-1P 648905-83-3P 648905-84-4P 649724-98-1P 861930-46-3P
866346-49-8P 866346-51-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(selective estrogen receptor modulator designed for treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries
in rats)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:740163 CAPLUS
DOCUMENT NUMBER: 141:265965
TITLE: Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride preparation as an antiestrogen
INVENTOR(S): Remick, David Michael
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075894	A1	20040910	WO 2004-US20	20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004009086	A1	20040129	WO 2003-IB303349	20030716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1782810	A2	20070509	EP 2006-122948	20030716
EP 1782810	A3	20070523		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
AU 2004216258	A1	20040910	AU 2004-216258	20040121
CA 2512663	A1	20040910	CA 2004-2512663	20040121
EP 1601356	A1	20051207	EP 2004-703963	20040121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007690	A	20060301	BR 2004-7690	20040121
CN 1753676	A	20060329	CN 2004-80005160	20040121
JP 2007537991	T	20071227	JP 2006-536491	20040121

US 2006167051	A1	20060727	US 2005-542872		20050720
IN 2005KN01530	A	20070413	IN 2005-KN1530		20050803
NO 2005004400	A	20050922	NO 2005-4400		20050922
PRIORITY APPLN. INFO.:			US 2003-450233P	P	20030225
			WO 2003-IB3349	A	20030716
			US 2002-397869P	P	20020722
			EP 2003-765254	A3	20030716
			WO 2003-IB303349	A	20030716
			WO 2004-US20	W	20040121

GI



I

AB The present invention relates to crystalline non-solvated 1-[4-(2-piperidinylethoxy)phenoxy]-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene-HCl (I), useful as a selective estrogen receptor modulator. I was prepared, formulated in tablets, as pharmacol. tested for estrogen antagonist activity.

IT 648904-58-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride preparation as an antiestrogen)

RN 648904-58-9 CAPLUS

CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



IC ICM A61K031-4453
ICS A61P005-32; C07D295-08
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 27
IT 648904-58-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride preparation as an antiestrogen)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80504 CAPLUS
DOCUMENT NUMBER: 140:128285
TITLE: Preparation of (sulfonylphenylnaphthyl)-substituted piperidines as selective estrogen receptor modulators
(SERMs) for treating endometriosis and/or uterine leiomyoma
INVENTOR(S): Dally, Robert Dean; Dodge, Jeffrey Alan; Frank, Scott
Alan; Jones, Scott Alan; Shepherd, Timothy Alan; Wallace, Owen Brendan; Fong, Kin Chiu; Hummel, Conrad

	Wilson; Lewis, Geroge Sal
PATENT ASSIGNEE(S):	Eli Lilly and Company, USA
SOURCE:	PCT Int. Appl., 118 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009086	A1	20040129	WO 2003-IB3349	20030716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490580	A1	20040129	CA 2003-2490580	20030716
AU 2003253129	A1	20040209	AU 2003-253129	20030716
BR 2003012675	A	20050503	BR 2003-12675	20030716
EP 1530470	A1	20050518	EP 2003-765254	20030716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668303	A	20050914	CN 2003-817201	20030716
JP 2005538089	T	20051215	JP 2004-522648	20030716
EP 1782810	A2	20070509	EP 2006-122948	20030716
EP 1782810	A3	20070523		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
NZ 537138	A	20071130	NZ 2003-537138	20030716
AU 2004216258	A1	20040910	AU 2004-216258	20040121
CA 2512663	A1	20040910	CA 2004-2512663	20040121
WO 2004075894	A1	20040910	WO 2004-US20	20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601356	A1	20051207	EP 2004-703963	20040121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007690	A	20060301	BR 2004-7690	20040121
CN 1753676	A	20060329	CN 2004-80005160	20040121
JP 2007537991	T	20071227	JP 2006-536491	20040121

US 2006183736	A1	20060817	US 2005-521896		20050118
IN 2005KN00071	A	20060714	IN 2005-KN71		20050120
MX 2005PA00898	A	20050516	MX 2005-PA898		20050121
NO 2005000832	A	20050216	NO 2005-832		20050216
IN 2005KN01530	A	20070413	IN 2005-KN1530		20050803
NO 2005004400	A	20050922	NO 2005-4400		20050922
ZA 2005000586	A	20060329	ZA 2005-586		20060120
PRIORITY APPLN. INFO.:			US 2002-397869P	P	20020722
			US 2003-450233P	P	20030225
			EP 2003-765254	A3	20030716
			WO 2003-IB303349	A	20030716
			WO 2003-IB3349	W	20030716
			WO 2004-US20	W	20040121

OTHER SOURCE(S): MARPAT 140:128285

GI



I



II

AB Title compds. I [wherein m, p, and q = independently 0-2; n = 0-1; R = H

or COR2; R0 = independently OH, CF3, halo, alkyl, or alkoxy; R1 and R1' = independently alkyl, alkoxy, NR3R3a, CF3, or CH2CF3; or when n and q = 0, SO2R1 may combine with the Ph ring to form a heterocycle; R2 = alkyl, alkoxy, NR4R4, PhO, or (halo)phenyl; R3 = alkyl or Ph; R3a and R4 = independently H, alkyl, or Ph; X = O, CH2, or CO; X1 = O or NR5; R5 = H or alkyl; R8 = H or Me; with the provisos that if p = 1 or 2, then R8 = H and if p = 0, R8 = Me; Y = S, CH2CH2, or CH=CH; and pharmaceutical acid addition salts thereof] were prepared as selective estrogen receptor modulators (no data). For example, coupling of 4-(methanesulfonyl)phenylboronic acid with trifluoromethanesulfonic acid 6-methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester (preparation given) in the presence of CsF, Pd(OAc)2, and tricyclohexylphosphine in MeCN, followed by addition of MeOH, provided II (R = OMe) in 18% yield. Conversion of the piperidine derivative to its HCl salt (96%), demethylation using BBr3 in CH2C12 to give the alc. (85%), and recrystn. and treatment with 2M HCl in di-Et ether afforded II•HCl (R = OH) in 95% yield. In the antagonist mode of the Ishikawa cell proliferation assay, the latter blocked 70% of the estradiol-stimulated growth of human endometrial tumor cells. In addition, II•HCl (R = OH) inhibited estrogen-induced response when administered at 1.0 mg/kg in a 3-day rat uterus antagonist assay but did not significantly elevate circulating estradiol or LH levels in a 10-day rat hormone (ovarian stimulation) screen. Thus, I, and their pharmaceutical compns. are useful for treating endometriosis and/or uterine leiomyoma/leiomyomata.

IT 648904-56-7P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-79-4P, 6-[4-(Ethanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-88-5P, 6-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-91-0P,

5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(trifluoromethanesulfonyl)phenyl]naphthalen-2-ol 648905-08-2P 648905-11-7P, 6-[3-Chloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-15-1P, 6-[4-(Methanesulfonyl)-3-trifluoromethylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-18-4P, 6-[2,3-Dichloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-22-0P, 6-[3,4-Bis(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-

yl)ethoxy]phenoxy]naphthalen-2-ol 648905-25-3P,
5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(2,2,2-trifluoroethanesulfonyl)phenyl]naphthalen-2-ol 648905-29-7P,
5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-2-ylsulfonyl)phenyl]naphthalen-2-ol 648905-30-0P,
5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-2-ylsulfonyl)phenyl]naphthalen-2-ol hydrochloride 648905-39-9P,
6-[4-(Methanesulfonyl)-3-methylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-71-9P,
4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonic acid 2,2-dimethylpropyl ester 648905-90-2P,
6-[3,5-Difluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-96-8P,
5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-1-ylsulfonyl)phenyl]naphthalen-2-ol 648906-22-3P,
6-(3,5-Dimethyl-4-methylsulfonylphenyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648906-26-7P,
6-[4-(Methanesulfonyl)-3-(methylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648906-31-4P,
6-[4-(Cyclopropylsulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(selective estrogen receptor modulator; preparation of (sulfonylphenylnaphthyl)-substituted piperidines as SERMs for treating endometriosis and/or uterine leiomyoma)

RN 648904-56-7 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648904-79-4 CAPLUS
CN 2-Naphthalenol, 6-[4-(ethylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648904-88-5 CAPLUS
CN 2-Naphthalenol, 6-[3-fluoro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648904-91-0 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-[4-[(trifluoromethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 648905-08-2 CAPLUS
CN 2-Naphthalenol, 6-[3-methoxy-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-11-7 CAPLUS
CN 2-Naphthalenol, 6-[3-chloro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-15-1 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)-3-(trifluoromethyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-18-4 CAPLUS
CN 2-Naphthalenol, 6-[2,3-dichloro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 648905-22-0 CAPLUS
CN 2-Naphthalenol, 6-[3,4-bis(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-25-3 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-[4-[(2,2,2-trifluoroethyl)sulfonyl]phenyl]- (CA INDEX NAME)



RN 648905-29-7 CAPLUS
CN 2-Naphthalenol, 6-[4-[(1-methylethyl)sulfonyl]phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-30-0 CAPLUS
CN 2-Naphthalenol, 6-[4-[(1-methylethyl)sulfonyl]phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648905-39-9 CAPLUS
CN 2-Naphthalenol, 6-[3-methyl-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-71-9 CAPLUS
CN Benzenesulfonic acid,
4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-
2-naphthalenyl]-, 2,2-dimethylpropyl ester (CA INDEX NAME)



RN 648905-90-2 CAPLUS
CN 2-Naphthalenol, 6-[3,5-difluoro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-
piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648905-96-8 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-[4-(propylsulfonyl)phenyl]- (CA INDEX NAME)



RN 648906-22-3 CAPLUS
CN 2-Naphthalenol, 6-[3,5-dimethyl-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648906-26-7 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)-3-(methylthio)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



RN 648906-31-4 CAPLUS
CN 2-Naphthalenol, 6-[4-(cyclopropylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- (CA INDEX NAME)



IT 648904-58-9P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-78-3P, 6-[4-(Ethanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-87-4P, 6-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-92-1P,

5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(trifluoromethanesulfonyl)phenyl]naphthalen-2-ol hydrochloride 648905-07-1P, 6-[3-Hydroxy-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol trifluoroacetate 648905-12-8P, 6-[3-Chloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-14-0P, 6-[4-(Methanesulfonyl)-3-trifluoromethylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-17-3P, 6-[2,3-Dichloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-21-9P, 6-[3,4-Bis(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-26-4P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(2,2,2-trifluoroethanesulfonyl)phenyl]naphthalen-2-ol hydrochloride 648905-35-5P, 6-[4-(Methanesulfonyl)-2-methylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol trifluoroacetate 648905-38-8P, 6-[4-(Methanesulfonyl)-3-methylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-65-1P, N-tert-Butyl-4-[6-hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonamide hydrochloride 648905-67-3P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N,N-dimethylbenzenesulfonamide hydrochloride 648905-70-8P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonic acid 2,2-dimethylpropyl ester hydrochloride 648905-74-2P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N-methylbenzenesulfonamide hydrochloride 648905-77-5P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol methanesulfonate 648905-78-6P 648905-89-9P, 6-[3,5-Difluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-93-5P, 6-[4-(Methanesulfonyl)-3-methoxyphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-97-9P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-1-ylsulfonyl)phenyl]naphthalen-2-ol hydrochloride 648906-21-2P, 6-(3,5-Dimethyl-4-methylsulfonylphenyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648906-25-6P, 6-[4-(Methanesulfonyl)-3-(methylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648906-30-3P, 6-[4-(Cyclopropylsulfonyl)phenyl]-5-[4-[2-(piperidin-1-

yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(selective estrogen receptor modulator; preparation of (sulfonylphenylnaphthyl)-substituted piperidines as SERMs for treating endometriosis and/or uterine leiomyoma)

RN 648904-58-9 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648904-78-3 CAPLUS
CN 2-Naphthalenol, 6-[4-(ethylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648904-87-4 CAPLUS
CN 2-Naphthalenol, 6-[3-fluoro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648904-92-1 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-[4-[(trifluoromethyl)sulfonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648905-07-1 CAPLUS
CN 2-Naphthalenol, 6-[3-hydroxy-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 648905-06-0
CMF C30 H31 N O6 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 648905-12-8 CAPLUS
CN 2-Naphthalenol, 6-[3-chloro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648905-14-0 CAPLUS
CN 2-Naphthalenol,
6-[4-(methylsulfonyl)-3-(trifluoromethyl)phenyl]-5-[4-[2-
(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648905-17-3 CAPLUS
CN 2-Naphthalenol, 6-[2,3-dichloro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● HCl

RN 648905-21-9 CAPLUS
CN 2-Naphthalenol, 6-[3,4-bis(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648905-26-4 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-[4-[(2,2,2-trifluoroethyl)sulfonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648905-35-5 CAPLUS
CN 2-Naphthalenol, 6-[2-methyl-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 648905-34-4
CMF C31 H33 N O5 S

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 648905-38-8 CAPLUS
CN 2-Naphthalenol, 6-[3-methyl-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648905-65-1 CAPLUS
CN Benzenesulfonamide, N-(1,1-dimethylethyl)-4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-naphthalenyl]-, monohydrochloride (9CI) (CA
INDEX NAME)



RN 648905-67-3 CAPLUS
CN Benzenesulfonamide,
4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-
naphthalenyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 648905-70-8 CAPLUS
CN Benzenesulfonic acid,
4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-
2-naphthalenyl]-, 2,2-dimethylpropyl ester, hydrochloride (9CI) (CA INDEX
NAME)



RN 648905-74-2 CAPLUS
CN Benzenesulfonamide,
4-[6-hydroxy-1-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-
naphthalenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 648905-77-5 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, methanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 648904-56-7
CMF C30 H31 N O5 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 648905-78-6 CAPLUS
CN Butanedioic acid, compd. with 6-[4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-naphthalenol (1:1) (CA INDEX NAME)

CM 1

CRN 648904-56-7
CMF C30 H31 N O5 S



CM 2

CRN 110-15-6
CMF C4 H6 O4

$HO_2C-CH_2-CH_2-CO_2H$

RN 648905-89-9 CAPLUS
CN 2-Naphthalenol, 6-[3,5-difluoro-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648905-93-5 CAPLUS
CN 2-Naphthalenol, 6-[3-methoxy-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648905-97-9 CAPLUS
CN 2-Naphthalenol, 5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-6-[4-(propylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 648906-21-2 CAPLUS
CN 2-Naphthalenol, 6-[3,5-dimethyl-4-(methylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648906-25-6 CAPLUS
CN 2-Naphthalenol, 6-[4-(methylsulfonyl)-3-(methylthio)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 648906-30-3 CAPLUS
CN 2-Naphthalenol, 6-[4-(cyclopropylsulfonyl)phenyl]-5-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



IC ICM A61K031-4453
ICS A61P005-32; C07D295-08; C07D333-56; C07D333-72; C07D295-12; C07D333-64
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
IT 648904-52-3P,
1-[2-[4-[[2-[4-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-54-5P, 1-[2-[4-[[2-[4-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine Hydrochloride 648904-56-7P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-62-5P, 2,2-Dimethylpropionic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648904-66-9P, Benzoic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648904-68-1P, 4-Fluorobenzoic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648904-72-7P, Carbonic acid isobutyl ester 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648904-74-9P, Methylcarbamic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648904-76-1P, 1-[2-[4-[[2-[4-(Ethanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine hydrochloride 648904-77-2P,

1-[2-[4-[[2-[4-(Ethanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-79-4P, 6-[4-(Ethanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-80-7P, 1-[2-[4-[[2-[3-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-82-9P, 6-[3-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-86-3P, 1-[2-[4-[[2-[3-Fluoro-4-(methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-88-5P, 6-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648904-90-9P, 1-[2-[4-[[6-Methoxy-2-[4-(trifluoromethanesulfonyl)phenyl]naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-91-0P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(trifluoromethanesulfonyl)phenyl]naphthalen-2-ol 648904-94-3P, 1-[2-[4-[[2-(1,1-Dioxo-2,3-dihydro-1H-benzo[b]thiophen-5-yl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-96-5P, 6-(1,1-Dioxo-2,3-dihydro-1H-benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-08-2P 648905-10-6P, 1-[2-[4-[[2-[3-Chloro-4-(methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-11-7P, 6-[3-Chloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-13-9P 648905-15-1P, 6-[4-(Methanesulfonyl)-3-trifluoromethylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-16-2P, 1-[2-[4-[[2-[2,3-Dichloro-4-(methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-18-4P, 6-[2,3-Dichloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-20-8P, 1-[2-[4-[[2-[3,4-Bis(methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-22-0P, 6-[3,4-Bis(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-24-2P, 1-[2-[4-[[6-Methoxy-2-[4-(2,2,2-trifluoroethanesulfonyl)phenyl]naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-25-3P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(2,2,2-trifluoroethanesulfonyl)phenyl]naphthalen-2-ol 648905-28-6P, 6-[4-(Isopropylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-29-7P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-2-ylsulfonyl)phenyl]naphthalen-2-ol 648905-30-0P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-2-ylsulfonyl)phenyl]naphthalen-2-ol hydrochloride 648905-31-1P, 1-[2-[4-[[6-Methoxy-2-[2-methyl-4-(methylsulfanyl)phenyl]naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine hydrochloride 648905-32-2P,

1-[2-[4-[[6-Methoxy-2-[2-methyl-4-(methylsulfanyl)phenyl]naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-33-3P, 6-[2-Methyl-4-(methylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-36-6P, 1-[2-[4-[[6-Methoxy-2-[3-methyl-4-(methylsulfanyl)phenyl]naphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-37-7P,
6-[3-Methyl-4-(methylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-39-9P,
6-[4-(Methanesulfonyl)-3-methylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-40-2P, 1-[2-[4-[[2-(Benzo[b]thiophen-5-yl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-41-3P,
6-(Benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-43-5P, Acetic acid
6-(1,1-dioxo-1H-benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648905-44-6P,
6-(1,1-Dioxo-1H-benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-48-0P, 6-[3,5-Bis(ethylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-49-1P, 6-[3,5-Bis(ethanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-55-9P, [4-[[2-[4-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenyl][2-(piperidin-1-yl)ethyl]carbamic acid tert-butyl ester 648905-60-6P 648905-62-8P 648905-64-0P, N-tert-Butyl-4-[6-methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonamide 648905-66-2P,

4-[6-Methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N,N-dimethylbenzenesulfonamide 648905-69-5P, 4-[6-Benzyloxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonic acid 2,2-dimethylpropyl ester 648905-71-9P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonic acid 2,2-dimethylpropyl ester 648905-72-0P,
N-tert-Butyl-4-[6-methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N-methylbenzenesulfonamide 648905-73-1P, 4-[6-Methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N-methylbenzenesulfonamide 648905-76-4P, Isobutyric acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[[2-(piperidin-1-yl)ethyl]oxy]phenoxy]naphthalen-2-yl ester 648905-81-1P,

[2-[4-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl][4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone 648905-83-3P,
[2-[4-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl][4-[2-(piperidin-1-yl)ethoxy]phenyl]methanol 648905-84-4P,
[2-[4-(Methanesulfonyl)phenyl]-6-methoxynaphthalen-1-yl][4-[2-(piperidin-1-yl)ethoxy]phenyl]methane 648905-88-8P,

1-[2-[4-[[2-[3,5-Difluoro-4-(methanesulfonyl)phenyl]-6-methoxynaphthalen-1-

yl]oxy]phenoxy]ethyl]piperidine 648905-90-2P, 6-[3,5-Difluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-92-4P, Acetic acid 6-[4-(methanesulfonyl)-3-methoxyphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester 648905-94-6P, 1-[2-[4-[[2-[4-(Propylsulfanyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-95-7P, 6-[4-(Propylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648905-96-8P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-1-ylsulfonyl)phenyl]naphthalen-2-ol 648906-05-2P, 1-[2-[4-[[6-Benzyloxy-2-[4-(ethanesulfonyl)phenyl]benzo[b]thiophen-3-yl]oxy]phenoxy]ethyl]piperidine 648906-06-3P, 2-[4-(Ethanesulfonyl)phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol 648906-10-9P, 2-[4-(Methanesulfonyl)phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol 648906-12-1P, 1-[2-[4-[[6-Benzyloxy-2-[3-fluoro-4-(methanesulfonyl)phenyl]benzo[b]thiophen-3-yl]oxy]phenoxy]ethyl]piperidine 648906-15-4P, 1-[2-[4-[[6-Benzyloxy-2-[4-(trifluoromethanesulfonyl)phenyl]benzo[b]thiophen-3-yl]oxy]phenoxy]ethyl]piperidine 648906-16-5P, 3-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-2-[4-(trifluoromethanesulfonyl)phenyl]benzo[b]thiophen-6-ol 648906-20-1P, 1-[2-[4-[[2-(3,5-Dimethyl-4-methylsulfonylphenyl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648906-22-3P, 6-(3,5-Dimethyl-4-methylsulfonylphenyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648906-24-5P, 1-[2-[4-[[2-[4-(Methanesulfonyl)-3-(methylsulfanyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648906-26-7P, 6-[4-(Methanesulfonyl)-3-(methylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648906-29-0P, 1-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-2-[4-(cyclopropylsulfonyl)phenyl]-6-methoxynaphthalene 648906-31-4P, 6-[4-(Cyclopropylsulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol 648906-34-7P, 1-[2-[4-[[2-[4-(Methanesulfonyl)phenyl]-6-methoxy-3,4-dihydronaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(selective estrogen receptor modulator; preparation of (sulfonylphenylnaphthyl)-substituted piperidines as SERMs for treating endometriosis and/or uterine leiomyoma)

IT 648904-58-9P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-60-3P, 2,2-Dimethylpropionic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester hydrochloride 648904-64-7P, Benzoic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-

(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester hydrochloride 648904-70-5P, 4-Fluorobenzoic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester hydrochloride 648904-73-8P, Carbonic acid isobutyl ester 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester hydrochloride 648904-75-0P, Methylcarbamic acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester hydrochloride 648904-78-3P, 6-[4-(Ethanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-81-8P, 6-[3-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-87-4P, 6-[3-Fluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-92-1P,

5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(trifluoromethanesulfonyl)phenyl]naphthalen-2-ol hydrochloride 648904-95-4P, 6-(1,1-Dioxo-2,3-dihydro-1H-benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648904-98-7P, 1-[2-[4-[[2-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophen-5-yl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648904-99-8P,

6-(2,2-Dioxo-2,3-dihydro-1H-benzo[c]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-05-9P,

1-[2-[4-[[2-[4-(Methanesulfonyl)-3-methoxyphenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-07-1P, 6-[3-Hydroxy-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol trifluoroacetate 648905-12-8P, 6-[3-Chloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-14-0P, 6-[4-(Methanesulfonyl)-3-trifluoromethylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-17-3P, 6-[2,3-Dichloro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-21-9P, 6-[3,4-Bis(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-26-4P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(2,2,2-trifluoroethanesulfonyl)phenyl]naphthalen-2-ol hydrochloride 648905-27-5P, 1-[2-[4-[[2-[4-(Isopropylsulfanyl)phenyl]-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine 648905-35-5P, 6-[4-(Methanesulfonyl)-2-methylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol trifluoroacetate 648905-38-8P, 6-[4-(Methanesulfonyl)-3-methylphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-42-4P, 6-(Benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol trifluoroacetate 648905-45-7P, 6-(1,1-Dioxo-1H-benzo[b]thiophen-5-yl)-5-[4-[2-(piperidin-1-

yl)ethoxy]phenoxy]naphthalen-2-ol trifluoroacetate 648905-56-0P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[[2-(piperidin-1-yl)ethyl]amino]phenoxy]naphthalen-2-ol Dihydrochloride 648905-57-1P 648905-61-7P 648905-65-1P, N-tert-Butyl-4-[6-hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonamide hydrochloride 648905-67-3P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N,N-dimethylbenzenesulfonamide hydrochloride 648905-70-8P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]benzenesulfonic acid 2,2-dimethylpropyl ester hydrochloride 648905-74-2P, 4-[6-Hydroxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl]-N-methylbenzenesulfonamide hydrochloride 648905-75-3P, Isobutyric acid 6-[4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester hydrochloride 648905-77-5P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol methanesulfonate 648905-78-6P 648905-82-2P,

[6-Hydroxy-2-[4-(methanesulfonyl)phenyl]naphthalen-1-yl][4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride 648905-85-5P, 6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]benzyl]naphthalen-2-ol hydrochloride 648905-89-9P, 6-[3,5-Difluoro-4-(methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-93-5P, 6-[4-(Methanesulfonyl)-3-methoxyphenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648905-97-9P, 5-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-6-[4-(propan-1-ylsulfonyl)phenyl]naphthalen-2-ol hydrochloride 648906-07-4P, 2-[4-(Ethanesulfonyl)phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol hydrochloride 648906-09-6P, 1-[2-[4-[[6-Benzyloxy-2-[4-(methanesulfonyl)phenyl]benzo[b]thiophen-3-yl]oxy]phenoxy]ethyl]piperidine trifluoroacetate 648906-11-0P, 2-[4-(Methanesulfonyl)phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol hydrochloride 648906-14-3P, 2-[3-Fluoro-4-(methanesulfonyl)phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]benzo[b]thiophen-6-ol trifluoroacetate 648906-17-6P,

3-[4-[2-(Piperidin-1-yl)ethoxy]phenoxy]-2-[4-(trifluoromethanesulfonyl)phenyl]benzo[b]thiophen-6-ol trifluoroacetate 648906-21-2P, 6-(3,5-Dimethyl-4-methylsulfonylphenyl)-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648906-25-6P, 6-[4-(Methanesulfonyl)-3-(methylsulfanyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648906-30-3P, 6-[4-(Cyclopropylsulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-ol hydrochloride 648906-35-8P,

6-[4-(Methanesulfonyl)phenyl]-5-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]-7,8-dihydronaphthalen-2-ol

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(selective estrogen receptor modulator; preparation of (sulfonylphenylnaphthyl)-substituted piperidines as SERMs for treating endometriosis and/or uterine leiomyoma)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.82	214.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.80	-4.80

STN INTERNATIONAL LOGOFF AT 15:25:56 ON 06 JAN 2008